JP2018517774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517774A5 JP2018517774A5 JP2018517123A JP2018517123A JP2018517774A5 JP 2018517774 A5 JP2018517774 A5 JP 2018517774A5 JP 2018517123 A JP2018517123 A JP 2018517123A JP 2018517123 A JP2018517123 A JP 2018517123A JP 2018517774 A5 JP2018517774 A5 JP 2018517774A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- therapeutically effective
- per day
- eczema
- nicotinamide riboside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 23
- 208000017520 skin disease Diseases 0.000 claims 17
- 201000004624 Dermatitis Diseases 0.000 claims 15
- 208000010668 atopic eczema Diseases 0.000 claims 15
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 14
- 235000020956 nicotinamide riboside Nutrition 0.000 claims 14
- 239000011618 nicotinamide riboside Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 11
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims 11
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- 201000004681 Psoriasis Diseases 0.000 claims 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 230000036561 sun exposure Effects 0.000 claims 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 3
- 208000034656 Contusions Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 3
- 208000019872 Drug Eruptions Diseases 0.000 claims 3
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 claims 3
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 3
- 206010014970 Ephelides Diseases 0.000 claims 3
- 206010059284 Epidermal necrosis Diseases 0.000 claims 3
- 206010015218 Erythema multiforme Diseases 0.000 claims 3
- 208000010201 Exanthema Diseases 0.000 claims 3
- SSLYUYACQWNDET-UHFFFAOYSA-N F.I Chemical compound F.I SSLYUYACQWNDET-UHFFFAOYSA-N 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 3
- 206010020649 Hyperkeratosis Diseases 0.000 claims 3
- 208000001126 Keratosis Diseases 0.000 claims 3
- 208000005995 Lichenoid Eruptions Diseases 0.000 claims 3
- 206010064000 Lichenoid keratosis Diseases 0.000 claims 3
- 208000003351 Melanosis Diseases 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 201000011152 Pemphigus Diseases 0.000 claims 3
- 206010034972 Photosensitivity reaction Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 3
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims 3
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 3
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 3
- 206010042496 Sunburn Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 206010047642 Vitiligo Diseases 0.000 claims 3
- 206010000496 acne Diseases 0.000 claims 3
- 208000004631 alopecia areata Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 3
- 208000034526 bruise Diseases 0.000 claims 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- ONTQJDKFANPPKK-UHFFFAOYSA-L chembl3185981 Chemical compound [Na+].[Na+].CC1=CC(C)=C(S([O-])(=O)=O)C=C1N=NC1=CC(S([O-])(=O)=O)=C(C=CC=C2)C2=C1O ONTQJDKFANPPKK-UHFFFAOYSA-L 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000010247 contact dermatitis Diseases 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- 201000001981 dermatomyositis Diseases 0.000 claims 3
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 claims 3
- 201000005884 exanthem Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 3
- 229920000159 gelatin Polymers 0.000 claims 3
- 239000008273 gelatin Substances 0.000 claims 3
- 235000019322 gelatine Nutrition 0.000 claims 3
- 235000011852 gelatine desserts Nutrition 0.000 claims 3
- 235000011187 glycerol Nutrition 0.000 claims 3
- 230000005484 gravity Effects 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 229960003943 hypromellose Drugs 0.000 claims 3
- 201000011486 lichen planus Diseases 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 201000005962 mycosis fungoides Diseases 0.000 claims 3
- 239000004006 olive oil Substances 0.000 claims 3
- 235000008390 olive oil Nutrition 0.000 claims 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 3
- 230000036211 photosensitivity Effects 0.000 claims 3
- 239000008213 purified water Substances 0.000 claims 3
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 3
- 206010037844 rash Diseases 0.000 claims 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 3
- 201000003385 seborrheic keratosis Diseases 0.000 claims 3
- 210000002374 sebum Anatomy 0.000 claims 3
- 239000000377 silicon dioxide Substances 0.000 claims 3
- 235000012239 silicon dioxide Nutrition 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 229940005741 sunflower lecithin Drugs 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 239000004408 titanium dioxide Substances 0.000 claims 3
- 235000010215 titanium dioxide Nutrition 0.000 claims 3
- 231100000331 toxic Toxicity 0.000 claims 3
- 230000002588 toxic effect Effects 0.000 claims 3
- 235000013311 vegetables Nutrition 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 230000037303 wrinkles Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173733P | 2015-06-10 | 2015-06-10 | |
| US62/173,733 | 2015-06-10 | ||
| PCT/US2016/019653 WO2016200447A1 (en) | 2015-06-10 | 2016-02-25 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517774A JP2018517774A (ja) | 2018-07-05 |
| JP2018517774A5 true JP2018517774A5 (enExample) | 2019-04-04 |
Family
ID=57503873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517123A Pending JP2018517774A (ja) | 2015-06-10 | 2016-02-25 | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11426398B2 (enExample) |
| EP (1) | EP3307754B1 (enExample) |
| JP (1) | JP2018517774A (enExample) |
| KR (1) | KR20180021784A (enExample) |
| CN (1) | CN107849083A (enExample) |
| AU (2) | AU2016274126A1 (enExample) |
| CA (1) | CA2989115C (enExample) |
| ES (1) | ES2932801T3 (enExample) |
| MX (2) | MX389207B (enExample) |
| RU (1) | RU2017145692A (enExample) |
| TW (1) | TWI725033B (enExample) |
| WO (1) | WO2016200447A1 (enExample) |
| ZA (1) | ZA201800056B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018517774A (ja) | 2015-06-10 | 2018-07-05 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| EP4049656B1 (en) * | 2017-03-17 | 2025-01-29 | Elysium Health, Inc. | Combination of nicotinamide riboside and pterostilbene for use in treating or preventing liver damage |
| US20180303861A1 (en) * | 2017-04-24 | 2018-10-25 | Eric Marcotulli | Treating and preventing kidney damage |
| WO2018213420A1 (en) * | 2017-05-17 | 2018-11-22 | Universitat De Valencia-Estudi General | Treating and preventing motor neuron diseases using nicotinamide riboside |
| WO2018213715A1 (en) * | 2017-05-18 | 2018-11-22 | Elysium Health, Inc. | Methods and compositions for improving sleep |
| CN111542312A (zh) * | 2017-07-28 | 2020-08-14 | 老龄化控制中心股份公司 | 预防和逆转衰老方面的组合物和方法 |
| CN109589309A (zh) * | 2017-09-30 | 2019-04-09 | 浙江嘉华化工有限公司 | 烟酰胺核糖微囊的制备方法 |
| WO2019079686A1 (en) * | 2017-10-19 | 2019-04-25 | Elysium Health, Inc. | PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH TDP-43 |
| EP3717500A1 (en) * | 2017-12-01 | 2020-10-07 | Elysium Health, Inc. | Methods and compositions for treating multiple sclerosis |
| WO2019108875A1 (en) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Methods and compositions for treating glaucoma |
| GB201811312D0 (en) * | 2018-07-10 | 2018-08-29 | Nuchido Ltd | Compositions |
| US11802103B2 (en) | 2018-09-25 | 2023-10-31 | Ponce De Leon Health Designated Activity Company | Process of making calcium alpha-ketoglutarate |
| CN111569084B (zh) * | 2019-02-19 | 2021-07-13 | 中国科学院上海药物研究所 | 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途 |
| US12350283B2 (en) * | 2019-02-26 | 2025-07-08 | Universitat De Valencia-Estudi General | Methods and compositions for treating motor neuron diseases |
| WO2020190703A1 (en) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Methods for wound treatment |
| CN113768946A (zh) * | 2020-05-25 | 2021-12-10 | 南京帝昌医药科技有限公司 | 一种治疗糖尿病皮肤并发症的软膏及其制备方法 |
| CN113712193A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 修复皮肤系统的组合物制备方法及其用途 |
| WO2022026612A1 (en) * | 2020-07-30 | 2022-02-03 | Hernandez Vazquez Moises | Nutritional supplements for repairing muscle and defending against deterioration from human aging |
| WO2023012182A1 (en) * | 2021-08-02 | 2023-02-09 | Nuvamid Sa | Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP3730507A1 (en) | 2005-11-18 | 2020-10-28 | Cornell Research Foundation, Inc. | Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors |
| EP2322159A1 (en) * | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| WO2012129499A1 (en) | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Treatment of inflammatory and infectious skin disorders |
| US8841350B2 (en) * | 2011-05-11 | 2014-09-23 | ChromaDex Inc. | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| US20130296440A1 (en) * | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| MX385305B (es) * | 2013-10-30 | 2025-03-18 | Chromadex Inc | Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel. |
| JP6559713B2 (ja) | 2014-06-06 | 2019-08-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ニコチンアミドリボシド類似体ならびにその医薬組成物および使用 |
| MX390185B (es) | 2015-03-16 | 2025-03-20 | Chromadex Inc | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. |
| WO2016149277A1 (en) | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| JP2018517774A (ja) | 2015-06-10 | 2018-07-05 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
-
2016
- 2016-02-25 JP JP2018517123A patent/JP2018517774A/ja active Pending
- 2016-02-25 CA CA2989115A patent/CA2989115C/en active Active
- 2016-02-25 CN CN201680046668.7A patent/CN107849083A/zh active Pending
- 2016-02-25 US US15/735,066 patent/US11426398B2/en active Active
- 2016-02-25 KR KR1020187000353A patent/KR20180021784A/ko not_active Ceased
- 2016-02-25 AU AU2016274126A patent/AU2016274126A1/en not_active Abandoned
- 2016-02-25 EP EP16807940.8A patent/EP3307754B1/en active Active
- 2016-02-25 RU RU2017145692A patent/RU2017145692A/ru unknown
- 2016-02-25 MX MX2017016024A patent/MX389207B/es unknown
- 2016-02-25 ES ES16807940T patent/ES2932801T3/es active Active
- 2016-02-25 WO PCT/US2016/019653 patent/WO2016200447A1/en not_active Ceased
- 2016-06-13 TW TW105118370A patent/TWI725033B/zh active
-
2017
- 2017-12-08 MX MX2021012600A patent/MX2021012600A/es unknown
-
2018
- 2018-01-04 ZA ZA2018/00056A patent/ZA201800056B/en unknown
-
2020
- 2020-12-08 AU AU2020286208A patent/AU2020286208B2/en active Active
-
2022
- 2022-07-25 US US17/872,575 patent/US12109206B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517774A5 (enExample) | ||
| RU2017145692A (ru) | Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи | |
| Guo et al. | Antinociceptive and anti-inflammatory activities of ethyl acetate fraction from Zanthoxylum armatum in mice | |
| JP2018537513A5 (enExample) | ||
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| US9913817B2 (en) | Methods for preventing or reducing colon carcinogenesis | |
| MX373042B (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| Bai et al. | Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| CN102389423A (zh) | 一种含有布洛芬钠盐的药用组合物 | |
| Xiao et al. | Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities | |
| RU2008126212A (ru) | Матричная таблетка с модифицированным высвобождением | |
| JP2016527307A5 (enExample) | ||
| RU2020123899A (ru) | Новые соединения, ингибирующие mtor | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2016505050A5 (enExample) | ||
| MX391602B (es) | Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| JP2015509934A5 (enExample) | ||
| CN111315370A (zh) | 一种具有抗炎症性肠病作用的药物及其制备方法和应用 | |
| CN115368425A (zh) | 三萜类化合物及其制备方法与抗炎用途 | |
| JP2019511996A5 (enExample) |